testosterone cypionate half life

With the development testosterone cypionate half life of a serious allergic reaction filgrastim therapy should be discontinued.In patients receiving filgrastim described isolated cases of sickle cell crises, some – with a fatal outcome (see “Precautions” section.).In patients receiving G-CSF (filgrastim) describes individual cases splenic rupture in healthy donors and patients with cancer (see. “Safety Precautions” section).

Described rare cases (more than or equal to 0.01% and less than 0.1%) Sweet’s syndrome (acute febrile dermatosis).

Patients with cancer in patients receiving filgrastim individual cases described of pseudogout (chondrocalcinosis).

Laboratory parameters: in patients receiving cytotoxic filgrastim after chemotherapy, there was a reversible increase in the concentration of uric acid in serum, activity of alkaline phosphatase and lactate dehydrogenase without clinical signs (generally mild or moderate).

Interaction with other drugs

Safety and efficacy of administration of Neupogen ® on the same day as myelosuppressive cytotoxic chemotherapy drugs, have not been established. In view of the sensitivity of rapidly dividing myeloid cells to myelosuppressive cytotoxic chemotherapy, prescribe  before or after the administration of these drugs is not recommended in the range of 24 hours. When concomitant administration of the drug  and fluorouracil severity of neutropenia may be exacerbated. Possible interactions with other hematopoietic growth factors and cytokines is unknown.

Given that lithium promotes the release of neutrophils, may increase the action of the drug with combined appointment, but such studies have not been conducted.

Increased haematopoietic activity of the bone marrow in response to growth factor treatment results in a transient positive bone imaging changes during that should be taken into account when interpreting the results.

Because of the incompatibility of the pharmaceutical should not be mixed with sodium chloride 0.9%.

Features of the drug by pregnant women, women during the period of breastfeeding, children and adults with chronic diseases

 

Security testosterone cypionate half life has not been established for pregnant women. Perhaps the passage of the drug  through the placental barrier in women. In animal studies, reproductive toxicity was identified. In appointing the drug  pregnant should be related to the expected therapeutic effect of the possible risk to the fetus.

In studies in rats of both sexes were not observed any influence on the fertility and pregnancy when applying filgrastim at doses up to 500 mg / kg.

In studies on rats and rabbits  did not have a teratogenic effect. In rabbits, there was an increased incidence of miscarriage, but fetal abnormalities were noted.

It is not known whether  passes into breast milk. Use  in nursing mothers is not recommended.

Elderly age

The study involved a small number of elderly patients, special studies of this group of patients have not been conducted. Specific recommendations for elderly patients are missing.

Evaluation of safety and efficacy of  in over 60 years has not been evaluated healthy donors.

Children

Standard regimens of cytotoxic chemotherapy: the safety profile and efficacy of the drug testosterone cypionate half life in children receiving cytotoxic chemotherapy, did not differ from those of adults.

Patients after myelosuppressive or myeloablative therapy followed by autologous transfusion PSCC: assessment of safety and efficacy of  in healthy donors under the age of 16 years has not been evaluated.

Patients with TXH and cancer: efficacy and safety of  in infants suffering TXH not installed.

Severe congenital, periodic or idiopathic neutropenia (ANC less than or equal to 0.5 x 10 9 / l) is an indication for prolonged use of the drug Neupogen ® in children with severe or recurrent infections history to increase the number of neutrophils, as well as to reduce the frequency and duration of complications associated with infection (see. “readings” section).

In clinical trials, efficacy was proven  in patients under the age of 18 years TXH and cancer. The safety profile of the drug in children for the treatment of TXH not differ from that in adults.

Dosing recommendations for pediatric patients are the same as for adults receiving myelosuppressive cytotoxic chemotherapy.

Patients with renal or hepatic insufficiency

No dose adjustment is required in patients with severe renal or hepatic impairment, as their pharmacokinetic and pharmacodynamic indices were similar to those of healthy volunteers.

Effects on ability to drive vehicles and working with machines and mechanisms
There was no effect of testosterone cypionate half life the ability to drive a car or operate machinery.

the ability to drive a car or operate machinery.